Accurately predicting the vaccine market

Posted on Nov 9, 2021

Today, AstraZeneca's Q3 figures were released stating that its COVID-19 Vaccine revenue reached $1.05bn in revenue.

To Airfinity subscribers this wasn’t a surprise as this was just 1% ($8m) off our official forecasts available through our platform. To put this into context, the analyst consensus predicted a more cautious $739m, which turned out to be $311m (30%) below the final amount. 

The future of the COVID-19 vaccine market has an enormous impact on the involved companies and the industry as a whole. 

We are offering a free 30 minute Q&A with a specialised vaccine analyst. You can request a session via our website:

To view our full 2022 COVID-19 Vaccine Revenue Forecast download for free here.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022